cjc-1295 ipamorelin synergy gh igf-1 Frontiers CJC-1295 + Ipamorelin | Benefits,
Description
The study groups (PD = all PD patients, de novo PD = PD patients who have not yet been treated with dopaminergic medication
This effect was independent from the dose of tirzepatide used and was similar in case of placebo [59] or treatment with active comparator semaglutide 1 mg [3]
Inoue K-i, Takano H
The gradual death of neurons, resulting in a loss of brain function, such as cognition, age-related dysregulation of biochemical pathways, and alterations of gene expression, is poorly understood and current therapies are still ineffective
The review calls for properly powered, placebo-controlled human trials before clinical recommendations can be made
